MERZ on the Move: Days After Ulthera Acquisition, Company Announces Plans for New Retinoid Therapy
Days after Ulthera acquisition, company announces plans to develop new Retinoid Therapy with Brickell Biotech.
Days after Ulthera acquisition, company announces plans to develop new Retinoid Therapy with Brickell Biotech.
New sizes for the Mia and Preserve systems expand the company’s minimally invasive breast offerings. The company also presented new clinical data on breast tissue preservation to more than 1,000 plastic surgeons.